You are here

Article Text

Article menu
Download PDFPDF
ABN Abstracts
PATH39 Malformation risks of antiepileptic drugs in pregnancy: an update from the UK Epilepsy and Pregnancy Register
  1. F Kennedy1,2,3,4,5,6,
  2. J Morrow1,2,3,4,5,6,
  3. S Hunt1,2,3,4,5,6,
  4. A Russell1,2,3,4,5,6,
  5. W H Smithson1,2,3,4,5,6,
  6. L Parsons1,2,3,4,5,6,
  7. I Robertson1,2,3,4,5,6,
  8. B Irwin1,2,3,4,5,6,
  9. N Delanty1,2,3,4,5,6,
  10. P J Morrison1,2,3,4,5,6,
  11. J Craig1,2,3,4,5,6
  1. 1Royal Victoria Hospital Belfast, Belfast, UK
  2. 2Southern General Hospital Glasgow, University of Sheffield, Sheffield, UK
  3. 3Luton & Dunstable Hospital TR, Luton, UK
  4. 4Lancashire Teaching Hospitals NHS Trust, UK
  5. 5Beaumont Hospital, Dublin, Ireland
  6. 6Department of Genetics, Belfast City Hospital, Belfast, UK
  1. Correspondence to fionakennedy61280{at}hotmail.com

Abstract

Aim To assess the relative risk of major congenital malformations (MCM) from exposure to anti-epileptic drugs (AEDs) during pregnancy.

Methods 15 year prospective observational study from 1996 until 2009. The outcome measure is the MCM rate.

Results Informative outcomes were available for 5802 cases. The risk of MCM was significantly higher in women on AEDs during pregnancy (n=5376) in comparison to those on no treatment (n=426), RR: 1.55 (95% CI 1.13 to 2.14), and significantly higher in polytherapy (n=1183) than monotherapy (n=4193), RR: 1.60 (95% CI 1.19 to 2.15). The risk to those on valproate monotherapy was more than double that for those on either carbamazepine (RR 2.35, 95% CI 1.55 to 3.57) or lamotrigene (RR 2.40, 95% CI 1.57 to 3.68). 245 and 362 informative outcomes were obtained for topiramate and levetiracetam respectively, with MCM rates of 7.1% (95% CI 4.5 to 11.0%) and 2.5% (95% CI 1.3 to 4.7%). There were 3/83 cases of MCM in Topiramate monotherapy and 14/162 cases in polytherapy. There were no cases of MCMs in levetiracetam monotherapy and 9/229 cases levetiracetam polytherapy.

Conclusions AED exposure during pregnancy increases the risk of MCM in the babies of women with epilepsy. Polytherapy exposure has a higher risk than monotherapy. Valproate exposure carries higher MCM risk than any other AED. Lowest risk is associated with carbamazepine or lamotrigene monotherapy. Results for levetiracetam, although numbers are small, look promising.

https://doi.org/10.1136/jnnp.2010.226340.7

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.